Direct-to-consumer personal genome testing for age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 10, 2014, Pages 6167-6174

  Buitendijk, Gabri¨elle H S ^a   Amin, Najaf ^a   Hofman, Albert ^a,b   van Duijn, Cornelia M ^a   Vingerling, Johannes R ^a   Klaver, Caroline C W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NETHERLANDS GENOMICS INITIATIVE   (Netherlands)

Author keywords

Age related macular degeneration; AMD; DTC tests; Personal genome testing; Prediction

Indexed keywords

GENOMIC DNA;

ADULT; AGE RELATED MACULAR DEGENERATION; ANCESTRY GROUP; ARTICLE; BODY MASS; CASE REPORT; DNA EXTRACTION; FEMALE; GENETIC ANALYSIS; GENETIC MARKER; GENETIC SCREENING; GENOTYPING TECHNIQUE; HUMAN; MALE; MIDDLE AGED; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VALIDATION STUDY; EPIDEMIOLOGY; EVALUATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOME; GENOTYPE; INCIDENCE; MACULAR DEGENERATION; NETHERLANDS; PROCEDURES; RISK ASSESSMENT;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME; GENOTYPE; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; NETHERLANDS; RISK ASSESSMENT;

EID: 84908105628     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15142     Document Type: Article

References (52)

1. Fritsche LG, Chen W, Schu M, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45: 433–439
2. Chen Y, Zeng J, Zhao C, et al. Assessing susceptibility to agerelated macular degeneration with genetic markers and environmental factors. Arch Ophthalmol. 2011;129:344–351
3. Gibson J, Cree A, Collins A, Lotery A, Ennis S. Determination of a gene and environment risk model for age-related macular degeneration. Br J Ophthalmol. 2010;94:1382–1387
4. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458–462
5. Grassmann F, Fritsche LG, Keilhauer CN, Heid IM, Weber BH. Modelling the genetic risk in age-related macular degeneration. PLoS One. 2012;7:e37979
6. Hageman GS, Gehrs K, Lejnine S, et al. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration. Hum Genomics. 2011;5:420–440
7. Jakobsdottir J, Conley YP, Weeks DE, Ferrell RE, Gorin MB. C2 and CFB genes in age-related maculopathy and joint action with CFH and LOC387715 genes. PLoS One. 2008;3:e2199
8. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet. 2009;5:e1000337
9. Klein ML, Francis PJ, Ferris FL III, Hamon SC, Clemons TE. Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol. 2011;129:1543–1550
10. McKay GJ, Dasari S, Patterson CC, Chakravarthy U, Silvestri G. Complement component 3: an assessment of association with AMD and analysis of gene-gene and gene-environment interactions in a Northern Irish cohort. Mol Vis. 2010;16: 194–199
11. Perlee LT, Bansal AT, Gehrs K, et al. Inclusion of genotype with fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic atrophy. Ophthalmology. 2013;120:1880–1892
12. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci. 2009; 50:5818–5827
13. Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009;50:2044–2053
14. Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology. 2011;118:2203–2211
15. Sharma NK, Sharma SK, Gupta A, Prabhakar S, Singh R, Anand A. Predictive model for earlier diagnosis of suspected agerelated macular degeneration patients. DNA Cell Biol. 2013;32: 549–555
16. Spencer KL, Olson LM, Schnetz-Boutaud N, et al. Using genetic variation and environmental risk factor data to identify individuals at high risk for age-related macular degeneration. PLoS One. 2011;6:e17784
17. Ying GS, Maguire MG. Development of a risk score for geographic atrophy in complications of the age-related macular degeneration prevention trial. Ophthalmology. 2011;118:332–338
18. Yu Y, Reynolds R, Rosner B, Daly MJ, Seddon JM. Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models. Invest Ophthalmol Vis Sci. 2012;53:1548–1556
19. Zanke B, Hawken S, Carter R, Chow D. A genetic approach to stratification of risk for age-related macular degeneration. Can J Ophthalmol. 2010;45:22–27
20. Hughes AE, Orr N, Patterson C, et al. Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking. PLoS Med. 2007;4:e355
21. Buitendijk GH, Rochtchina E, Myers C, et al. Prediction of agerelated macular degeneration in the general population: the Three Continent AMD Consortium. Ophthalmology. 2013; 120:2644–2655
22. Kalf RR, Mihaescu R, Kundu S, de Knijff P, Green RC, Janssens AC. Variations in predicted risks in personal genome testing for common complex diseases. Genet Med. 2013;16:85–91
23. Conley YP, Jakobsdottir J, Mah T, et al. CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses. Hum Mol Genet. 2006;15:3206–3218
24. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A. 2006;103:17456–17461
25. Laine M, Jarva H, Seitsonen S, et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol. 2007;178:3831–3836
26. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet. 2006;38:1055–1059
27. Skerka C, Lauer N, Weinberger AA, et al. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol. 2007;44:3398–3406
28. Sofat R, Casas JP, Webster AR, et al. Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol. 2012;41:250–262
29. Chen W, Stambolian D, Edwards AO, et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A. 2010;107:7401–7406
30. Neale BM, Fagerness J, Reynolds R, et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). Proc Natl Acad Sci U S A. 2010;107:7395–7400
31. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458–462
32. Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci U S A. 2007;104:16227–16232
33. Park KH, Fridley BL, Ryu E, Tosakulwong N, Edwards AO. Complement component 3 (C3) haplotypes and risk of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:3386–3393
34. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553–561
35. Spencer KL, Hauser MA, Olson LM, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet. 2007; 16:1986–1992
36. Macpherson MNB, Hsu A, Mountain J. White paper 23-31: Estimating genotype-specific incidence for one or several loci 2007. Available at: https://23andme.https.internapcdn.net/ res/pdf/HIC-SXIYiYqXreldAxO5yA_23-01_Estimating_ Genotype_Specific_Incidence.pdf. Accessed October 6, 2013
37. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007;39:1200–1201
38. Decod Eme. Risk calculation. Available at: http://www. decodeme.com/health-watch-information/risk-calculation. Accessed October 6, 2013
39. Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA. 2006;296:301–309
40. Jylhava J, Eklund C, Jylha M, et al. Complement factor H 402His variant confers an increased mortality risk in Finnish nonagenarians: the Vitality 90þ study. Exp Gerontol. 2009;44: 297–299
41. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39: 367–374
42. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98:1128–1134
43. ENIGMA2 GENETICS Support Team. ENIGMA2 1KGP Cookbook (v3). The Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) consortium. Available at: http:// enigma.ini.usc.edu/wp-content/uploads/2012/07/old/ ENIGMA2_1KGP_v3_old.pdf. Accessed December 17, 2013
44. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2010
45. WHO. Life expectancy at birth - 2011. Available at: http:// gamapserver.who.int/gho/interactive_charts/mbd/life_ expectancy/atlas.html. Accessed December 19, 2013
46. Prioux F, Barbieri M. Recent demographic developments in France: relatively low mortality at advanced ages. Population (Engl Ed). 2012;67
47. Nonyane BA, Nitsch D, Whittaker JC, et al. An ecological correlation study of late age-related macular degeneration and the complement factor H Y402H polymorphism. Invest Ophthalmol Vis Sci. 2010;51:2393–2402
48. Ricci F, Zampatti S, D’Abbruzzi F, et al. Typing of ARMS2 and CFH in age-related macular degeneration: case-control study and assessment of frequency in the Italian population. Arch Ophthalmol. 2009;127:1368–1372
49. NCBI. dbSNP. Available at: http://www.ncbi.nlm.nih.gov/ projects/SNP/snp_ref.cgi?rs¼800292. Accessed December 20, 2013
50. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 2003;121:519–526
51. Vingerling JR, Hofman A, Grobbee DE, Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol. 1996;114:1193–1196
52. FDA: US Food and Drug Administration. Medical Devices. US Department of Health and Human Services 2014. Available at: http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/InVitroDiagnostics/default. htm. Accessed June 30, 2014.